NASDAQ
05.06.26 | 19:51
0,880 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TELA BIO Aktie jetzt für 0€ handeln | |||||
| 13.05. | TELA Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | Tela Bio verfehlt Q1-Prognosen: Aktie gibt nach | 1 | Investing.com Deutsch | ||
| 12.05. | TELA Bio Q1 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| 12.05. | TELA Bio GAAP EPS of -$0.21 misses by $0.02, revenue of $19.1M beats by $0.1M | 1 | Seeking Alpha | ||
| 12.05. | TELA Bio, Inc.: TELA Bio Reports First Quarter 2026 Financial Results | 141 | GlobeNewswire (Europe) | MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 12.05. | TELA Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.04. | TELA Bio, Inc.: TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues | 215 | GlobeNewswire (Europe) | MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| 21.04. | TELA Bio, Inc.: TELA Bio to Announce First Quarter 2026 Financial Results | 2 | GlobeNewswire (USA) | ||
| 27.03. | Citizens cuts Tela Bio stock price target on commercial transition | 2 | Investing.com | ||
| 25.03. | TELA Bio Analysts Cut Their Forecasts After Q4 Results | 1 | Benzinga.com | ||
| 25.03. | TELA Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 25.03. | TELA Bio, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 25.03. | Piper Sandler cuts TELA Bio stock price target on lowered outlook | 1 | Investing.com | ||
| 25.03. | Piper Sandler senkt Kursziel für TELA Bio nach schwächerem Ausblick | 1 | Investing.com Deutsch | ||
| 25.03. | Jefferies senkt Kursziel für TELA Bio wegen schwächerer Wachstumsaussichten | 2 | Investing.com Deutsch | ||
| 25.03. | Jefferies cuts TELA Bio stock price target on slower growth outlook | 2 | Investing.com | ||
| 25.03. | Tela Bio targets at least 8% revenue growth in 2026 while advancing commercial transformation | 1 | Seeking Alpha | ||
| 24.03. | TELA Bio: Gewinn übertrifft Erwartungen, doch Umsatz enttäuscht - Aktie bricht ein | - | Investing.com Deutsch | ||
| 24.03. | TELA Bio GAAP EPS of -$0.17 beats by $0.01, revenue of $20.9M misses by $0.14M | 2 | Seeking Alpha | ||
| 24.03. | TELA Bio, Inc.: TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results | 443 | GlobeNewswire (Europe) | MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 41,190 | +0,12 % | Opening Bell: Bitcoin, Strategy, Broadcom, Marvell, Micron, Axon Enterprise, Moderna, Lululemon | Die US-Börsen haben am Donnerstag eine zweigeteilte Entwicklung gezeigt. Der Dow Jones eröffnete mit klaren Gewinnen, baute diese im Verlauf deutlich aus und schloss 1,73 Prozent fester. Der Nasdaq... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 13,800 | +0,88 % | Improving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to Buy | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,235 | -1,56 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 8-K, Current Report | ||
| MYRIAD GENETICS | 4,050 | +2,02 % | Myriad Genetics, Inc.: Myriad Genetics Names Raj Jampa as New Chief Technology Officer | SALT LAKE CITY, June 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces today the appointment of Raj Jampa... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,055 | -0,47 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update | Key Development Agreements Secured for Nonclinical Toxicology and U.S. cGMP Clinical Supply ManufacturingKing of Prussia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Phio Pharmaceuticals Corp.... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,645 | -0,06 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| TC BIOPHARM | 0,825 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.04.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.04.2026ISIN NameCA0211551068 ALSET... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 254,00 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 35,590 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| JADE BIOSCIENCES | 16,940 | 0,00 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen | |
| QIAGEN | 31,920 | -2,18 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Feedback aus Gesprächen mit etlichen US-Laborexperten deute darauf hin, dass... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 86,86 | -0,07 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| ADMA BIOLOGICS | 7,970 | 0,00 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 14,755 | -0,10 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| ERASCA | 11,970 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen |
Das Unternehmen TELA BIO INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,880 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELA BIO INC finden Sie auf Wallstreet Online.